The president also may not be the last Trump to run for elected office.Donald Trump Jr. and Ivanka Trump may hold future political aspirations, and that could curb some plans for growth. The risks are greatest on the international front, where potential for conflicts of interest abound. The investigations could also lead to negative publicity as the company is looking to expand.A new stream of business partners may emerge with Mr. Trump out of the spotlight.Over the past four years, Bobby R. Burchfield, a Washington lawyer, served as the Trump Organization’s ethics adviser, scrutinizing potential deals and business partners. The examinations made it difficult for some to pass muster, while others were scared off by the public attention.- Advertisement – That scrutiny will now fall away, opening a pipeline of new partners.And with more than $300 million in debt coming due that the president has personally guaranteed, there may be some urgency for the Trump Organization to line up new deals. In addition, an adverse ruling in an audit battle with the Internal Revenue Service could cost him more than $100 million, The Times reported in September.A polarized country and the pandemic could hamper a rebound.Some of Mr. Trump’s most lucrative properties are in Democratic strongholds, like New York and Chicago, where he remains deeply unpopular. And his biggest revenue-generator, his Doral golf resort in Florida, has suffered from a drop-off in conference revenue as some big companies and organizations stayed away because of his divisiveness.- Advertisement – As president, Mr. Trump has tried to fill the gap, at least in part, through events booked at his properties by groups connected to him and Republican politics. The Trump International Hotel near the White House was often brimming with partisan allies.It is unclear if that patronage will continue, or if Mr. Trump’s detractors will return to his properties once he leaves office. Additionally, it has been a tough year for the hospitality industry because of the pandemic, and the headwinds have hit commercial real estate, too. Both are central to Mr. Trump’s business portfolio.There may be another presidential act for Mr. Trump or his children.Mr. Trump, as of late, has privately raised the idea of running again in 2024. And the possibility of another Trump presidential run could have a chilling effect on his business in the intervening years, at least in countries like China, where a thicket of ethical and legal conflicts could arise.- Advertisement – – Advertisement –
– Advertisement – The NBTC site doesn’t provide specific details about the Realme 7 5G. However, if it were to be rebadged Realme V5, we can expect an identical list of specifications. Tipster Abhishek Yadav on Twitter has additionally leaked pricing details of the unannounced phone.Realme 7 5G price (expected)As per the leak, the Realme 7 5G will be priced at CNY 1,499 (roughly Rs. 17,000) for the 6GB RAM + 128GB storage variant, while its 8GB RAM + 128GB storage version would carry a price tag of CNY 1,899 (roughly Rs. 21,400).Realme 7 5G specifications (expected)In terms of specifications, the Realme 7 5G is said to have a 6.5-inch display with a 90Hz refresh rate, a hole-punch design, and an octa-core MediaTek Dimensity 720 SoC. The phone is also tipped to come with quad rear cameras that include a 48-megapixel primary sensor, an 8-megapixel secondary sensor, along with two other 2-megapixel sensors. Tipster Abhishek Yadav also mentioned that the Realme 7 5G would come with a 16-megapixel selfie camera sensor at the front. Furthermore, the smartphone is said to have a 5,000mAh battery with 30W fast charging, side-mounted fingerprint sensor, 3.5mm headphone jack, and 9.1mm of thickness. All these specifications are identical to those of the Realme V5.- Advertisement – Realme 7 5G is likely to be the next model in the Realme 7 series that has Realme 7, 7 Pro, and 7i. While Realme hasn’t officially provided any details, the new smartphone has reportedly received a certification from the National Broadcasting and Telecommunications Commission (NBTC) of Thailand. The details on the NBTC site suggests that the Realme 7 5G could just be a global variant of the Realme V5.As initially reported by tipster Sudhanshu Ambhore, the NBTC site shows that the Realme 7 5G could carry model number RMX2111. This was previously associated with the Realme V5 that debuted in China in August.- Advertisement – Why are smartphone prices rising in India? We discussed this on Orbital, our weekly technology podcast, which you can subscribe to via Apple Podcasts, Google Podcasts, or RSS, download the episode, or just hit the play button below.
Tolbert, for his part, told fans via Roper’s Instagram Story in May that he was “content” with two children and expanding their family was “not planned” at the time they discovered they were expecting. “But now this happens, so we’re gonna have three,” he shared. “I’m like, ‘What’s the difference between three and four?’”Listen to Here For the Right Reasons to get inside scoop about the Bachelor franchise and exclusive interviews from contestants Another little Tolbert! Jade Roper introduced the world to her and husband Tanner Tolbert’s third child together just hours after his arrival.“He’s here and he’s perfect,” the Bachelor alum, 33, captioned an Instagram photo of herself holding the baby boy on Saturday, November 14. The couple, who are also parents of daughter Emerson, 3, and son Brooks, 15 months, have yet to announce the newborn’s name.- Advertisement – Tolbert, 33, revealed via his Instagram Story on Saturday that Roper gave birth earlier that morning. “5:33 AM,” he wrote after sharing videos of the reality star in labor. “Mama and Baby Boy doing great!” She appeared to deliver the baby at home, as fans saw her sitting in an inflatable pool in the pair’s bedroom prior to the birth. (She notably had an emergency home birth with their second child in July 2019.)Roper hinted that her third child’s arrival was imminent on Thursday, November 12. “I’ll be 39 weeks pregnant on Sunday, and I have to say I’m so proud of my body for carrying this far!” she explained on Instagram. “I was so much more intentional this pregnancy with taking care of myself, and I feel like it paid off, because this is the most pregnant I’ve ever been! I’m full of so many different emotions as each night I wonder if we will be meeting our baby. Last night Emmy reached up, grabbed my belly and sweetly said, ‘It’s time to come out, baby.’ #soon #babywatch.”The duo, who wed in January 2016, announced their pregnancy news in May. She divulged via Instagram in June that she expects baby No. 3 to be their “last,” noting: “[I want] to soak up every moment (laughing at myself when I say this cuz our kids keep us crazy busy lol) and document everything since it’ll be the last of the firsts.”- Advertisement – – Advertisement – – Advertisement –
May 22, 2006 (CIDRAP News) – Clinicians should use oseltamivir (Tamiflu) as first-line treatment for H5N1 avian influenza, but they should consider giving one of the older antiviral drugs along with it in some circumstances, the World Health Organization (WHO) recommends.In new guidelines issued May 19, the WHO also said physicians should consider using one of the older drugs—amantadine or rimantadine—as first-line therapy if newer drugs are not available and surveillance indicates local strains of the H5N1 virus are susceptible to the drugs.”This is the first time we clearly state the possibility of dual therapy to be considered in case you are facing an H5N1 outbreak,” said Nahoko Shindo, a WHO medical officer who helped draw up the guidelines, as quoted in a May 19 Reuters report.The guidelines address the use of the neuraminidase inhibitors (NIs), including oseltamivir and zanamivir (Relenza), and the M2 inhibitors—amantadine and rimantadine—in treating patients with known or suspected H5N1 infection. The M2 inhibitors, also known as adamantanes, are cheaper than the NIs, but they have not previously been recommended for use in H5N1 cases because the likelihood of viral resistance was considered too high.However, recent data suggest that some strains of H5N1 are susceptible to the older drugs. An analysis of more than 600 H5N1 viruses collected in Southeast Asia showed that most samples from China and Indonesia lacked genetic characteristics signaling resistance to amantadine, whereas most samples from Vietnam, Thailand, and Cambodia had those characteristics. The report was published by the Journal of Infectious Diseases.The new WHO guidelines were drawn up by an international group of clinicians with experience treating H5N1 patients, along with other experts, at a meeting in late March. The panel systematically reviewed and graded the evidence for the drugs’ effectiveness.Evidence rated as slimSince no results from controlled trials of medication use in H5N1 cases are available, “Overall, the quality of the underlying evidence for all recommendations was very low,” the 138-page WHO report states. The evidence includes results of lab and animal studies and indirect evidence from studies of antiviral use in patients with seasonal influenza. The recommendations are classified as “strong” or “weak,” depending on the quality of the relevant evidence.The WHO says that if a patient has a confirmed or strongly suspected H5N1 case and NIs are available, “Clinicians should administer oseltamivir treatment (strong recommendation); zanamivir might be used as an alternative (weak recommendation).”Oseltamivir comes in capsule form, whereas zanamivir is taken with an inhaler. The WHO says zanamivir has lower bioavailability outside the respiratory tract than oseltamivir, but it may be active against some strains of oseltamivir-resistant H5N1 virus.The guidelines say clinicians should not use amantadine or rimantadine alone as first-line treatment if neuraminidase inhibitors are available. However, “Clinicians might administer a combination of a neuraminidase inhibitor and an M2 inhibitor if local surveillance data show that the H5N1 virus is known or likely to be susceptible (weak recommendation).”If clinicians try this combination therapy, they should collect “detailed and standardized clinical and virological data” from the start of treatment, the document adds.If NIs are not available, the WHO advises, “Clinicians might administer amantadine or rimantadine as a first-line treatment if local surveillance data show that the H5N1 virus is known or likely to be susceptible to these drugs (weak recommendation).” The report adds that rimantadine generally has a better side-effect profile than amantadine.The guidelines say that for now, the recommendations on using antivirals for treatment of H5N1 cases are the same as those for early treatment of adults and children with seasonal influenza.However, the US Centers for Disease Control and Prevention advised physicians last January to stop using amantadine and rimantadine for the rest of the flu season, because the dominant flu strain had become highly resistant to them. More than 90% of influenza A(H3N2) isolates had become resistant, the agency said at the time.Preventive use of antiviralsThe WHO also issued recommendations on preventive use of the antiviral drugs in people with potential exposure to H5N1 (postexposure prophylaxis).The agency said that where available, oseltamivir or zanamivir should be used preventively in high- and moderate-risk exposure groups, including pregnant women, continuing for 7 to 10 days after exposure. The drugs probably should not be used prophylactically in low-risk exposure groups, the document says. High-risk groups are defined as household or close family contacts of a strongly suspected or confirmed H5N1 patient.Amantadine and rimantadine should not be used preventively if NIs are available, the WHO advises. But if NIs are not available, the older drugs could be used in high- and moderate-risk groups if local surveillance data show that the virus is likely to be susceptible to them.The WHO authors also looked at the possible use of other supplementary treatments in H5N1 cases, including corticosteroids, immunoglobulin, interferon, and ribavirin. “There was no basis to make a recommendation for use of any of these medicines outside the context of a randomised trial, but ribavirin particularly should not be used in pregnant women (strong recommendation),” the report says.See also:Full text of WHO guidelineshttp://www.who.int/medicines/publications/WHO_PSM_PAR_2006.6.pdfMay 12 CIDRAP News story “Study suggests older antivirals could help fight H5N1”
Jun 20, 2006 (CIDRAP News) – A 13-year-old boy from south Jakarta who died Jun 14 represented Indonesia’s 51st avian influenza case and was the 39th Indonesian to succumb, according to a World Health Organization (WHO) statement today.His death leaves Indonesia only three fatalities behind Vietnam, which has reported the most H5N1 deaths in the world but hasn’t had a human case since late last year, according to WHO information.The boy—who has been listed as 14 years old in various news stories—experienced symptoms Jun 9 and was hospitalized Jun 13, the WHO update said. His symptoms began 1 week after he helped his grandfather slaughter chickens.The grandfather has shown no signs of flu, and the WHO is tracing and monitoring contacts to ensure that no further cases arise, the agency said.The official worldwide death toll from H5N1 avian flu has now reached 130, among 228 cases, according to the WHO.WHO confirmation of the teen’s case comes a day before a 3-day conference in Jakarta of experts from the WHO, UN Food and Agriculture Organization, the US Centers for Disease Control and Prevention, the Indonesian ministries of health and agriculture, and other organizations worldwide.The consultation, which is being held at the request of Indonesian officials and attended by more than 40 experts, will review Indonesia’s efforts to contain avian flu, provide an authoritative risk assessment for both animals and people, and give advice to improve the situation, the WHO said. Indonesia is reporting new H5N1 cases faster than any other country.The Jun 21-23 meeting will also examine epidemiologic and virologic data collected during the month-long investigation into the extended-family H5N1 case cluster in North Sumatra, which killed 6 of 7 infected family members in May, the WHO reported today. An eighth family member who died is suspected to have succumbed to avian flu as well.Experts from laboratories that tested samples from the family will present their findings at the meeting, the WHO said. Several viruses have been isolated from the samples and have been fully sequenced at WHO reference labs in Hong Kong and the United States.More than 3 weeks (twice the maximum H5N1 incubation period) have passed since the last infected family member died, and no new cases have been reported, the WHO update said. The agency had conducted house-to-house monitoring throughout the family’s village and in healthcare facilities where the patients were treated.Indonesia has been criticized for not doing enough to stem the tide of avian flu, according to an article from Agence France-Presse (AFP) today. H5N1 has been found in birds in the vast majority of the nation’s far-flung provinces, but few mass culls have been carried out as recommended by the United Nations, the AFP story said.”Within 6 months, we have to do more practical culling . . . there’s no other alternative,” Trisatya Naipospos, vice chairperson of Indonesia’s committee on bird flu control, said in an AFP story yesterday.Today, however, the head of Indonesia’s avian flu task force, in the ministry of agriculture, predicted better days ahead.”In 2008, Indonesia will be free from bird flu,” said Delima Ashari, according to a Reuters article today. But he added, “I realize that the immense size of Indonesia makes it not easy to handle and socialize strategies and change people’s behavior on bird flu handling and how to live healthily with fowl.”See also:Jun 20 WHO update on Indonesian situationhttp://www.who.int/csr/don/2006_06_20/en/index.html
Webster RG, Govorkova EA. H5N1 influenza–continuing evolution and spread. (Perspective) N Engl J Med 2006 Nov 23;355(21):2174-7 [Full text](CIDRAP Source Weekly Briefing) – Certain recent new stories may have sown confusion about whether the threat of pandemic influenza still exists, and whether the world needs to continue to prepare. A New England Journal of Medicine article published last week provides the antidote, and the answer: It does, and we do.Reknowned avian flu expert Robert G. Webster, PhD, and colleague Elena Govorkova, MD, PhD, enumerate several factors that support the conclusion that the situation is worsening, not abating.These factors include an increasing number of countries affected [add link to graphic], ever increasing genetic differences within H5N1 “clades” (subgroups of the deadly form of avian flu virus), antiviral drug resistance, lack of adequate disease control in developing countries, imperfect poultry vaccinations, and continued infection in waterfowl.Webster and Govorkova point out that H5N1 originated in Southeast Asia, similar to the origin of the last two pandemics in 1957 and 1968.The authors also explain how the H5N1 virus has emerged into two clades (clades 1 and 2) or genetically distinct viruses, the latter of which is further divided into three subclades. Unfortunately, these H5N1 categories differ enough genetically that a vaccine against one is unlikely to provide protection against the others.The authors do suggest that protection offered by a vaccine against one clade may offer some benefit against death if the pandemic is caused by other clades or subclades. Thus, they believe that it is “worth stockpiling” pre-pandemic vaccines, which differs from recent advice from the World Health Organization (WHO).Another obstacle to stopping the spread of avian influenza has been resistance to antivirals such as oseltamivir (Tamiflu). The authors point out that most of the clade 1 viruses are resistant, while most clade 2 viruses are not. Adding to the problem has been a delay in administering antivirals to patients with H5N1 infection in many instances, which may further promote natural selection of resistant strains because of high levels of virus in the patient’s body.The article also points out that, although controlling H5N1 influenza through culling and quarantining domestic poultry has worked for some wealthy countries such as Japan, that hasn’t been the case in poorer countries such as Thailand. Of note, in the past week, (The authors also mention South Korea’s success, but just within the past week it reported two separate H5N1 outbreaks in domestic poultry, calling into question the long-term effectiveness of Korea’s approach.)In addition, the authors do note that the effort to vaccinate uninfected poultry in conjunction with quarantine and culling by China, Indonesia, and Vietnam has failed, because the poultry vaccines are of poor quality, do not provide sufficient immunity, and promote genetic changes in the virus that may aid its spread.Webster and Govorkova point out that since Vietnam adopted a strategy of vaccinating all poultry with an inactivated (dead-virus), oil-emulsion H5N1 vaccine, there have been no additional cases in humans and no reported H5N1 infections in chickens.But in September 2006, H5N1 was reported to have emerged in ducks and geese in Vietnam, the report says.”Thus, H5N1 influenza vaccine seems to protect chickens, and indirectly, humans, but probably not waterfowl,” the writers state. The pair hypothesize that this could be the reason why H5N1 is not under control in China.”Clearly we must prepare for the possibility of an influenza pandemic,” the article concludes. “If H5N1 influenza achieves pandemic status in humans—and we have no way to know whether it will—the results could be catastrophic.”Comments from the Editor-in-Chief:Over recent months the No. 1 question that I am asked by many in the media and the general public goes something like this: “So, we don’t have to worry about that bird flu scare anymore . . . do we?” This perspective article by Webster and Govorkova should be required reading for each one of these questioners. It very clearly details why we should be even more concerned about the possibility of H5N1 causing the next pandemic than we were several years ago. It is a straightforward, balanced assessment of the current situation and is written so that every CEO can understand the message.
Jan 23, 2008 (CIDRAP News) – Health officials in Vietnam said today that a 32-year-old man has died of H5N1 avian influenza, signaling the country’s first reported case and death of the new year.The man was from northern Vietnam’s Tuyen Quang province, about 50 miles northwest of Hanoi, the Associated Press (AP) reported today. If his case is confirmed by the World Health Organization (WHO), he will be listed as Vietnam’s 102nd case-patient and its 48th fatality from the disease.To Doan Hong, of the provincial Preventive Medicine Center, told the AP that the man died last week, 2 days after he was admitted to the nation’s tropical disease hospital in Hanoi. Hong said the man got sick after slaughtering and cooking geese and chickens that had died on his backyard farm on Jan 9, according to the AP report. Samples from poultry were also positive for the virus, he said.Samples from the man’s family and neighbors have tested negative for the H5N1 virus, and officials have disinfected the man’s house, along with areas in his neighborhood, Hong told the AP.Tuyen Quang is one of four provinces that are currently on the Vietnamese government’s avian flu watch list, the AP report said.Vietnam’s last human H5N1 case was confirmed by the WHO on Dec 28. The patient was a 4-year-old boy from Son La province who died on Dec 16 after 5 days in the hospital. The WHO had said the source of the boy’s infection was still under investigation. The country has the second-highest avian flu case count, after Indonesia.In other developments, the WHO today confirmed Indonesia’s latest H5N1 case, that of a 32-year-old man from Tangerang, a suburb of Jakarta, who is being treated in a Jakarta hospital. His case raises the WHO’s H5N1 count for Indonesia to 120 cases with 97 deaths; the global count is 352 cases with 219 deaths.The man got sick on Jan 13 and was hospitalized 6 days later, according to a statement from the WHO. Investigators are trying to determine the source of his infection. According to a report yesterday from Indonesia’s National Committee for Avian Influenza Control and Pandemic Influenza Preparedness, the man is a sales executive at an automobile company.See also:Jan 23 WHO statementJan 22 CIDRAP News story “Indonesia reports another H5N1 case”
May 15, 2009 (CIDRAP News) – President Barack Obama’s appointment of New York City Health Commissioner Thomas Frieden, MD, MPH, to lead the Centers for Disease Control and Prevention (CDC) drew enthusiastic applause today from public health organizations and disease experts.Frieden, a tuberculosis expert, is credited with achievements as varied as helping improve tuberculosis control in India, driving trans-fats out of New York City restaurants, and reducing smoking in that city. He has headed the city’s Department of Health and Mental Hygiene (NYCDOH) since 2002.Dr. Richard Besser, who has served as acting CDC director since early in the Obama administration, will continue in his regular role as head of the CDC’s Coordinating Office for Terrorism Preparedness and Emergency Response, the White House announced. Frieden will assume the CDC post in early June.In a news release today, Obama said, “Dr. Frieden is an expert in preparedness and response to health emergencies, and has been at the forefront of the fight against heart disease, cancer and obesity, infectious diseases such as tuberculosis and AIDS, and in the establishment of electronic health records. Dr. Frieden has been a leader in the fight for health care reform, and his experiences confronting public health challenges in our country and abroad will be essential in this new role.”Public health leaders praised Frieden as an outstanding appointee who will base his policies on science and not shrink from difficult issues.”During his tenure as New York City’s health commissioner, Frieden has demonstrated an unwavering commitment to protecting the public’s health through his tireless work on issues ranging from implementing a ban on smoking in restaurants and bars to increasing HIV testing rates,” said Georges C. Benjamin, MD, executive director of the American Public Health Association, in a statement. “He has not backed away from the tough public health challenges and in doing so has helped the people he served lead healthier, longer lives.”Frieden is an Oberlin College graduate who earned medical and public health degrees at Columbia University, where he also trained in internal medicine before going to Yale University to study infectious diseases, according to information from the NYCDOH.He joined the NYCDOH in 1990 while working as a CDC Epidemic Intelligence Service officer on a wide range of issues. He led the city’s Bureau of Tuberculosis Control and served as assistant commissioner from 1992 to 1996, during which cases of multidrug-resistant TB in the city dropped by 80%, according to the NYCDOH.Frieden subsequently worked in India for 5 years, helping with the nation’s TB control program, which has treated more than 8 milloin patients and saved more than a million lives, the NYCDOH said.Frieden has been credited with numerous initiatives in his time as health commissioner. New York was the nation’s first city “to eliminate trans-fats from restaurants, rigorously monitor the diabetes epidemic, and reqeuire certain restaurants to post calorie information prominently,” the health department said.The White House said Frieden has led efforts that have reduced the number of smokers in New York by 350,000, increased cancer screening, reduced AIDS deaths by 40%, and implemented the largest community electronic health records project in the nation. “Dr. Frieden and his team have responded effectively to several urgent health problems, including cases of anthrax, plague, and, most recently, H1N1 influenza,” the statement said.Dr. Anne Gershon, president of the Infectious Disease Society of America (IDSA), said in an IDSA statement that she has been “incredibly impressed with Dr. Frieden’s response to the recent influenza A H1N1 outbreak and previous outbreaks of other diseases.” Gershon is a pediatric infectious disease specialist at Columbia University in New York.In an interview, Gershon said Frieden has taken a very organized approach to the novel H1N1 situation, holding teleconferences with infectious disease physicians to keep them abreast of events.”In a situatoin like this it would be very easy to just panic and close schools and do things that are not necessarily indicated, and he’s been able to control that,” Gershon said. “I think he’s wonderful in being able to delegate responsibility to highly competent people so he knows the job is being done well.”Frieden has shown an ability to get people from diverse groups to work together well, Gershon added.Giving an example of his problem-solving skills, Gershon said the city at one point had a problem with cases of neonatal herpes that were related to circumcisions. “He cleared that up and did it in a very nice way, without having people getting angry at each other. . . . It was a serious issue, and it stopped. The people he delegated to deal with this, day to day, were terrific. I think that tells you something about him.”Frieden won praise from other infectious disease experts as well.In the IDSA statement, Roy Gulick, MD, chief of infectious diseases at Weill Medical College of Cornell University, predicted that Frieden would forcefully advocate using evidence-based practices in the battle against HIV-AIDS. In New York he has emphasized prevention by promoting needle exchange and condom use and has worked hard to promote routine HIV testing, Gulick said.Richard P. Wenzel, MD, a former IDSA president, told CIDRAP News, “This individual is a proven achiever with high standards and appropriate, epidemiologically based priorities. He is an excellent choice.” Wenzel is chair of internal medicine at Virginia Commonwealth University in Richmond.The Trust for America’s Health, a nonprofit public health policy group in Washington, DC, also applauded Frieden’s appointment.”Dr. Frieden is a bold leader who has the courage to shake up the status quo if science and evidence show that change needs to happen,” said Jeff Levi, PhD, TFAH executive director, in a statement. “He doesn’t shy away from the tough problems. His innovative strategies have led to real reductions in smoking rates, diabetes, HIV/AIDS, tuberculosis, and food-borne illness in New York City.”During the campaign, President Obama made a commitment to make policy decisions based on the integrity of science. With this appointment, the President has taken an important step to fulfill this promise,” Levi said.See also: May 15 White House press releaseMay 15 APHA statementFrieden biography from NYCDOH
Based on the better results and the constant increase in the number of passengers at Rijeka Airport, the management of Eurowings has decided to introduce a regular winter line that will connect Rijeka with Cologne throughout the year.After the introduction of year-round regular domestic routes (Split, Dubrovnik, Osijek) from the winter of 2016/2017, the coming winter brings a new year-round international line, which is sensational news for Rijeka Airport and its entire environment as in recent history Rijeka Airport it has never provided customers with the possibility of international lines throughout the year, but mostly only during the summer months.The introduction of winter lines represents a significant positive step forward for the entire county, its economy, residents, and especially all entities related to tourism, and in addition to all this, all passengers create the habit of easier and faster transfer throughout the year. Air connections are extremely important throughout the year for the development of tourism, as well as health tourism for which Rijeka and its surroundings have great potential and all the prerequisites.The official sale of tickets for these flights starts on July 8.7.2017, 10.11.2017, and they can be purchased on the Eurowings website. The first flight from Cologne to Rijeka starts on November 12, 35. at 14:40, with return from Rijeka to Cologne the same day at 10.11.2017:21.3.2018. During the entire winter period (November 10.11.2017, 1.12.2017 – March 12.1.2018, 16.2.2018), this line will take place twice a week, on Sundays and Fridays (November 6.12.2017, 3.1.2018 – December 21.2.2018, 21.3.2018 and January XNUMX, XNUMX – February XNUMX, XNUMX) and on Wednesdays. (XNUMX.-XNUMX. And XNUMX.-XNUMX.)
According to the proposal of the new law on road transport, the taxi market will be further liberalized, transport will be able to be ordered through the application, the restriction on the number of taxi permits will be abolished, and the price of services will be determined by carriers themselves.The bill is going into public debate from December 01, the debate will last a month, and it should be passed by the beginning of the next tourist season, ie around Easter next year, the ministry said, which estimates that it will undoubtedly provoke many reactions in the current taxi carriers which fundamentally change the way of doing business.The market is the best regulator, while the monopoly stifles entrepreneurship. The best regulator is the free market, the struggle of supply and demand, and price and quality.And there are always consumers to gain, because with the free market and competition we have the right to choose, a diverse offer and quality is raised as well as the price of a service or product is reduced. Then we can choose what suits us and our worldview. But the most important thing is that the market is only regulated because the market is the only first proof of success.As in everything, and so in this case, with the opening of the taxi market there was an increase in choice and different offers, lower prices, increase in the quality of transport services and most importantly increase the use of taxi services. Today we can choose whether we want more expensive or cheaper transport, we want ecological transport – we choose according to our capabilities and worldview. The market works, and the best are rewarded, while the worst, as in everything, are the least happy. There are two choices: Either raise the quality of service and learn in fair market competition like millions of other companies or retire. There is no third choice.The fight of the old monopolists of taxi transport against the competition and Uber is great, it means that they care, but not in this form as before, and especially not by violence and closing the streets with an argument because they don’t have that much work anymore. And who asks everyone else who struggles in the market every day to survive? A struggle that the former monopolists have long since lost, but are not yet aware of.Do we want a monopoly of one or a free market? This is a key issue, because looking from the perspective of taxi drivers who are fighting against the modern world and technology, then the former owners of video stores, as well as everyone else whose profession and profession has been replaced by technology, can rightly protest. The market is the best regulator, and the winners are always consumers.The new law will increase the number of taxi drivers in Croatia, because the current around 3.000 is certainly not enough for Croatia as a tourist country Thus, according to the new Act, carriers will choose the means they will use to charge for the ride, a taximeter or an electronic application. The ministry says that in the 21st century they could not go to the principle of prohibition, but also that public opinion polls showed that 85 percent of respondents voted for the application.It is estimated that the liberalization of the taxi market will at least double the number of taxi drivers, which is now around 3.000, which is too little for Croatia as a tourist country. Also, it is expected that the application of the new law will reduce the cost of taxi services, but also how to improve the quality of service, and a fair market competition will be opened where each carrier will find its niche business in accordance with its business policy.Future taxi drivers who do not have valid licenses will have to be at least 21 years old and have a good reputation, which means that they will not be able to taxi if they have been legally fined or if they have paid fines in excess of HRK 25.000 in the last two years. The future ordinance will also prescribe the age of taxi vehicles, and existing taxi drivers with their licenses can operate for another five years. A new initial driver qualification is also being introduced which will only be for taxis. Future taxi drivers will take a theoretical exam, and the obligation of a three-year vocational school will be abolished.The novelty is that local self-government units will have to issue licenses for performing taxi services in their area to all license holders, and not, as before, only to those from their area. This means that someone from continental Croatia will be able to legally taxi along the coast. The price of the permit may not exceed 10 percent of the monthly net salary in the area of the local self-government unit that issues the permit. The news is that taxi drivers who, for example, transport passengers from Zagreb to Velika Gorica, will be able to pick up a new passenger there as well.<br />
<a href=”https://bs.serving-sys.com/Serving/adServer.bs?cn=brd&pli=1074171063&Page=&Pos=-1477388646″ target=”_blank”><br />
<img src=”https://bs.serving-sys.com/Serving/adServer.bs?c=8&cn=display&pli=1074171063&Page=&Pos=-1477388646″ border=0 width=1280 height=200></a><br />